Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients

Shuo Wang,Xiujuan Qu,Zhi Li,Xiaofang Che,Lili Cao,Xianghong Yang,Xuejun Hu,Ling Xu,Kezuo Hou,Yibo Fan,Ti Wen,Yunpeng Liu
DOI: https://doi.org/10.21037/atm-20-968
IF: 3.616
2021-03-01
Annals of Translational Medicine
Abstract:BACKGROUND: Although immunotherapy has demonstrated similar clinical activities in the treatment of lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC), several studies have shown programmed death-ligand 1 (PD-L1) to have different predictive roles in ADC and SCC. This study was conducted to compare the different functions of PD-L1/programmed cell death protein 1 (PD-1) pathway in these malignancies.METHODS: A multi-dimensional analysis based on public databases and 2 independent cohorts including 262 patients with lung cancer was performed. Immunohistochemistry (IHC) and fluorescence-based multiplexed staining were used to detect the immune factors.RESULTS: PD-L1 was observed to have different expressions and regulatory mechanisms between SCC and ADC. PD-L1 was significantly increased from the messenger RNA (mRNA) to protein levels in the SCC group compared with the ADC group. Also, PD-L1 on tumor cells (TCs) was positively correlated with CD8<sup>+</sup> tumor lymphocyte infiltrates in ADC, but not in SCC. More importantly, PD-L1 was considered to be an independent predictor of overall survival (OS) for ADC patients. In contrast, in SCC patients, PD-1<sup>+</sup> tumor-infiltrating lymphocytes (TILs) were considered a poor prognostic predictor.CONCLUSIONS: These findings showed that PD-L1 in ADC and PD-1<sup>+</sup> TILs in SCC respectively indicates T-cell function, which plays a crucial role in determining prognosis. The distinct functions of the biomarkers between ADC and SCC might provide potential avenues for guiding anti-PD-1/PD-L1 immunotherapy.
oncology,medicine, research & experimental
What problem does this paper attempt to address?